EcoDrugPlus

Proteinase-Activated Receptor 1-Like

Ensembl ID : ENSATEG00000029426
Gene Symbol: LOC113159874
3 Cross references
265 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Src-Like

Ensembl ID : ENSATEG00000025083
Gene Symbol: LOC113154070
2 Cross references
191 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3a

Ensembl ID : ENSATEG00000012622
Gene Symbol: P2RX3A
1 Cross references
194 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3b

Ensembl ID : ENSATEG00000003860
Gene Symbol: P2RX3B
3 Cross references
200 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 7

Ensembl ID : ENSATEG00000009634
Gene Symbol: P2RX7
3 Cross references
195 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSATEG00000015327
Gene Symbol: P2RY1
3 Cross references
191 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSATEG00000016170
Gene Symbol: P2RY4
4 Cross references
168 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSATEG00000029335
Gene Symbol: P2RY6
3 Cross references
183 Possible Orthologues:

Receptor (Tnfrsf)-Interacting Serine-Threonine Kinase 1, Like

Ensembl ID : ENSATEG00000008438
Gene Symbol: RIPK1L
3 Cross references
198 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSATEG00000011922
Gene Symbol: RAMP1
3 Cross references
190 Possible Orthologues:

Receptor Activity-Modifying Protein 1-Like

Ensembl ID : ENSATEG00000025958
Gene Symbol: LOC113164205
2 Cross references
183 Possible Orthologues:

Receptor-Type Tyrosine-Protein Phosphatase Beta-Like

Ensembl ID : ENSATEG00000015475
Gene Symbol: LOC113165184
2 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).